Sutro Biopharma. has filed a patent for antibody conjugates targeting CD74, along with related compositions and methods for therapy. The patent claims have been canceled. GlobalData’s report on Sutro Biopharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Sutro Biopharma Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Sutro Biopharma, Nanoparticle drug conjugates was a key innovation area identified from patents. Sutro Biopharma's grant share as of January 2024 was 34%. Grant share is based on the ratio of number of grants to total number of patents.

Antibody conjugates targeting cd74 for therapy

Source: United States Patent and Trademark Office (USPTO). Credit: Sutro Biopharma Inc

The patent application (Publication Number: US20240026008A1) describes an antibody conjugate with a payload moiety linked to an antibody, specifically focusing on the presence of a non-natural amino acid at position LC-K42 in the light chain of the antibody. This non-natural amino acid can be selected from a variety of options, including para-azidomethylphenylalanine, p-acetyl-L-phenylalanine, and others listed in the claim. The conjugate can be linked via a hydrolytically stable or cleavable linker, with the payload moiety being a cytotoxic, cytostatic, or immunomodulatory agent such as maytansines, hemiasterlins, amanitins, or auristatins.

Furthermore, the patent application details the specificity of the antibody conjugate to CD74, its potential as a therapeutic agent for cancer treatment, and its various forms including monoclonal antibodies, IgA, IgD, IgE, IgG, or IgM antibodies. The antibody can be humanized or human, aglycosylated, or in fragment forms like Fv, Fab, F(ab')2, Fab', scFv (sFv), or scFv-Fc. Additionally, the application includes the provision of a kit containing the antibody conjugate for diagnostic assays related to cancer, infection, or autoimmune diseases, along with instructions for use. The kit may also include a detectable moiety for enhanced diagnostic capabilities. Moreover, a pharmaceutical composition comprising the antibody conjugate and a pharmaceutically acceptable carrier is also part of the patent application, emphasizing its potential in therapeutic procedures for cancer treatment.

To know more about GlobalData’s detailed insights on Sutro Biopharma, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies